RIGScan CR49

Identification

Name
RIGScan CR49
Accession Number
DB05437
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
International/Other Brands
RIGS CC49
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in colorectal cancer and solid tumors.

Pharmacodynamics
Not Available
Mechanism of action

RIGScan CR49 is used to locate cancerous tissue during surgery for patients with metastatic cancer of the colon or rectum (colorectal). In multicenter Phase II and pivotal Phase III clinical trials, RIGScan CR49 located tumor confirmed by pathology tests in 90 percent of evaluable patients who participated in the studies. The product found pathology-confirmed tumor that was missed by the surgeon and by preoperative diagnostic scans in one of five of the evaluable patients.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with RIGScan CR49.
AbituzumabThe risk or severity of adverse effects can be increased when RIGScan CR49 is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with RIGScan CR49.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with RIGScan CR49.
AducanumabThe risk or severity of adverse effects can be increased when RIGScan CR49 is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with RIGScan CR49.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with RIGScan CR49.
AlirocumabThe risk or severity of adverse effects can be increased when RIGScan CR49 is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when RIGScan CR49 is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when RIGScan CR49 is combined with AMG 108.
Food Interactions
Not Available

References

General References
  1. Arnold MW, Schneebaum S, Berens A, Petty L, Mojzisik C, Hinkle G, Martin EW Jr: Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg. 1992 Dec;216(6):627-32. [PubMed:1466615]
External Links
PubChem Substance
347910137

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:25 / Updated on November 02, 2018 06:10